CareDx Inc. stocks have been trading up by 12.84 percent following upbeat sentiment around its latest transplant diagnostics developments.
What Traders Need To Know
- Q2 2026 revenue hit $132M, up 52% year over year, driven by 61% growth in testing services and an average $1,720 per test.
- Profitability improved, with GAAP net income boosted by a $113M Lab Products divestiture gain and non-GAAP net income rising to $20M alongside $25M in adjusted EBITDA.
- Non-GAAP EPS jumped to $0.37 from $0.10 a year ago, topping the $0.23 consensus on revenue of $131.9M versus $86.7M last year and ahead of expectations.
- Management raised 2026 revenue guidance to $490–$500M and adjusted EBITDA guidance to $66–$78M, both well above prior targets and Street estimates near $456M in revenue.
- Shares spiked roughly 14–15% on heavy volume after the beat-and-raise quarter, signaling strong bullish momentum in CDNA.
Weekly Update Jul 27 – Jul 31, 2026: On Saturday, August 01, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 12.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
CareDx now screens as a focused, growth-stage diagnostics platform with improving fundamentals. Q2 revenue of $132M implies an annualized run-rate well above the trailing $380M, validating the 8.9–13.3% multi‑year CAGR and accelerating it materially. Gross margin near 69% is best‑in‑class, though historical EBIT and ROIC have been negative. The Lab Products divestiture, leaner opex and $30.6M operating cash flow drive positive free cash flow, backed by a strong balance sheet (current ratio 3.4x, minimal leverage).
Technically, CDNA has broken out violently from the mid‑$30s, with the 7/30 session printing a wide‑range candle (low ~$35.9, high ~$46.7, close $42) on surging volume, followed by constructive consolidation around $43. The dominant trend on the weekly timeframe is now firmly bullish. The key actionable level is $38–39, which aligns with the breakout zone; that should be used as buy‑on‑pullback support, with risk tightly managed below $36 on a closing basis.
More Breaking News
- ABEV Stock Slumps As Bank Of America Turns Bearish
- INSM Extends Brinsupri Global Reach As Traders Eye Guidance
- Rocket Companies RKT Stock Dips As Q3 Earnings Smash Estimates
- Ingersoll Rand Stock Draws Bullish Targets Amid Dividend Steadiness
Fundamentally and relative to diagnostics peers, the setup is compelling: revenue growth >50% YoY and rising EBITDA guidance ($66–78M) now compare favorably to broader healthcare and diagnostics benchmarks that are growing high single to low double digits with lower incremental margins. Near‑term catalysts include continued NavDx integration, CMS coverage tailwinds, and potential upside from cell therapy monitoring. I see upside toward $50–52 over 6–12 months, with near‑term support ~$38 and resistance in the mid‑$40s.
Quick Financial Overview
CareDx Inc. just posted the kind of beat-and-raise print that short-term traders look for. CDNA delivered Q2 2026 revenue of about $131.9M–$132M, a 52% year-over-year jump with testing services up 61%. That growth, plus an average revenue per test of $1,720, shows clear pricing power and strong demand in transplant and precision diagnostics. For traders, this confirms that the company’s shift toward higher-margin molecular testing is translating into real dollars.
On the bottom line, CDNA reported non-GAAP EPS of $0.37, up sharply from $0.10 a year earlier and well ahead of the $0.23 consensus. GAAP profitability was helped by a $113M gain from divesting the Lab Products business, but underlying non-GAAP net income still climbed to $20M and adjusted EBITDA reached $25M. That mix tells traders the quarter was not just an accounting win; operations are tightening, even though historical margins and returns have been negative.
Guidance is where the story really turned. CareDx Inc. lifted its 2026 revenue outlook to $490–$500M, far above roughly $455.9M that the Street was expecting, and raised adjusted EBITDA guidance to $66–$78M from $43–$57M. On the chart, the stock reflects that reset: after trading in the mid-$30s early in the week, CDNA spiked to an intraday high near the mid-$40s and closed around the low $43 area on 2026/07/31. The intraday 5-minute candle showing a push from the low $40s up toward $45 before settling back near $43.71 signals a classic earnings gap-and-run with some profit-taking into strength.
Conclusion
CareDx Inc. now sits at an interesting point for traders after the explosive Q2 move. The company’s fundamentals have stepped up: revenue is growing over 50% year over year, non-GAAP EPS is beating by a wide margin, and 2026 guidance for $490–$500M in revenue and $66–$78M in adjusted EBITDA is well ahead of prior expectations. At the same time, legacy ratios still show a story coming out of years of weak profitability, with thin historical margins and negative returns on capital, even as the balance sheet looks solid with low debt and strong liquidity.
From a price-action angle, CDNA’s jump from the mid-$30s to the low $40s, with an intraday spike toward the mid-$40s on heavy volume, marks a clear momentum shift. For short-term traders, the key questions are whether that earnings gap holds and how the stock behaves on any pullback toward the breakout zone around the high-$30s to low-$40s range. For swing traders, the raised guidance and focus on higher-margin precision diagnostics in transplant, specialty oncology, and cell therapy create a backdrop where positive surprises can continue, but the bar is now higher. In this context, it’s crucial to stay process-driven and avoid forcing trades based on bias or hope. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” That mindset can help traders wait for confirmation in both price action and fundamentals before committing capital.
CDNA’s risk/reward now revolves around execution against that aggressive 2026 outlook and the market’s willingness to pay for this new growth profile. For educational and research purposes, traders should track how revenue growth, test volumes, and EBITDA margin progress in coming quarters, and watch whether heavy-volume support returns on dips. As I tell my students, “The best trading edges show up when strong fundamentals, clear catalysts, and clean price action all line up—your job is to wait for that alignment, then manage risk with discipline.”
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.